Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

S-P Brings New Laxative Class To OTC Market Under Braintree Licensing Deal

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough will position Braintree Laboratories' MiraLAX laxative as an effective treatment for occasional constipation without "harsh" side effects linked to other OTC laxative products
Advertisement

Related Content

Research & Development In Brief
Sales & Earnings In Brief
OTC MiraLAX Must Contend With Prescription Competition – Court
Zegerid Study Shows Benefits For Immediate-Release PPI/Antacid
Schering-Plough
MiraLAX Joins Claritin As S-P OTC Sales Driver In Second Quarter
Expensive Rx Drugs Put Spotlight On OTC Opportunity – Economist
Clarinex OTC Option “Valuable” In Face Of Competition – Schering-Plough
Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal
Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS100035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel